Sun enjoys fleeting profit boost from oxaliplatin

Talk about a rollercoaster: Sun Pharma profits tripled in the first quarter, driven by one-time U.S. sales of chemotherapy drug oxaliplatin. But, alas, the generics maker stopped manufacturing the drug at the end of June, to avoid infringing the Sanofi Aventis patent. Sun has filed suit against Sanofi in the U.S. and says it will begin making the drug again in the event of a positive court ruling. Article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.